Eagle Pharmaceuticals, Inc. is a pharmaceutical firm primarily engaged in developing and bringing to market drug candidates for conditions affecting the central nervous system, metabolic critical care, and oncology within the U.S. Its current portfolio includes Ryanodex, used for malignant hyperthermia, and both Belrapzo and Bendeka, prescribed for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. The company's pipeline features several promising candidates: EP-4104, a dantrolene sodium formulation for organophosphate poisoning; PEMFEXY, a liquid, ready-to-use/dilute version of pemetrexed targeting non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and a Vasopressin injection aimed at elevating blood pressure in adults suffering from vasodilatory shock. Eagle Pharmaceuticals has forged licensing and collaboration pacts, including one with Combioxin, SA, covering the development and market rights for CAL02, an antitoxin designed to combat severe pneumonia alongside conventional antibiotics. Another agreement is with AOP Orphan Pharmaceuticals GmbH, granting commercial rights to Landiolol, an innovative therapeutic candidate for the temporary slowing of ventricular rate in patients experiencing supraventricular tachycardia, such as atrial fibrillation and atrial flutter. Furthermore, a strategic partnership exists with Tyme Technologies, Inc. for the advancement of SM-88, intended for treating HR+/HER2- breast cancer and high-risk metastatic sarcomas. Established in 2007, Eagle Pharmaceuticals, Inc. maintains its main office in Woodcliff Lake, New Jersey.
defenseworld.netCritical Contrast: Eagle Pharmaceuticals (NASDAQ:EGRX) & Indivior (OTCMKTS:INVVY)defenseworld.netApr 17
prnewswire.comDid Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.comApr 9
defenseworld.netEagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Above 50-Day Moving Average – Should You Sell?defenseworld.netMar 31